Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 13/20 | 0.66 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.38 |
| ▸ | GRK6 | P43250 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5465647 | 0.84 | CHEK1 (0.64) | CHEK1GRIN1GRIN2BPGRSLC6A11 | |
| SCHEMBL5478073 | 0.81 | CHEK1 (0.63) | CHEK1MAP3K7JAK2KDR | |
| SCHEMBL5465562 | 0.79 | CHEK1 (1.00) | CHEK1MAP3K7JAK2KDR | |
| SCHEMBL5469934 | 0.77 | CHEK1 (0.39) | CHEK1MAP3K7JAK2KDR | |
| SCHEMBL5795592 | 0.77 | ADORA1 (0.46) | CHEK1MAP3K7JAK2KDR | |
| SCHEMBL5475725 | 0.76 | CHEK1 (0.45) | CHEK1MAP3K7JAK2KDR | |
| SCHEMBL5483335 | 0.73 | KDM4E (0.44) | CHEK1KDM4EALDH1A1 | |
| SCHEMBL5480643 | 0.69 | CHEK1 (1.00) | CHEK1 | |
| SCHEMBL5470471 | 0.68 | CHEK1 (1.00) | CHEK1 | |
| SCHEMBL5469935 | 0.68 | CHEK1 (0.54) | CHEK1MAP3K7JAK2KDRGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | claimed |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | TP53, BRCA1, KLK3 | CHEK1 13/4885MAP3K7 923/4885JAK2 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.